Drugs / zonampanel
zonampanel
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00044070 | Dec 2000 → Jan 2003 | cerebral infarction | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00044057 | Dec 2000 → Jan 2003 | ischemic stroke | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zonampanel | “YM872 (zonampanel), t-PA (alteplase)” NCT00044057 ↗1“YM872 (zonampanel)” NCT00044070 ↗ |
| Known as | YM 872 ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL119625 ↗ |
| Known as | YM872 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00044070 ↗ |
| Known as | Zonampanel anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL119625 ↗ |
| Known as | Zonampanel monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL119625 ↗ |
| Modality | Small molecule | — CHEMBL119625 ↗ |
| Route | Intravenous | “YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.” NCT00044057 ↗ |